Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.936 EUR | +2.76% | -1.63% | -45.54% |
04-04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
04-03 | AB Science: reconsideration possible for masitinib in ALS | CF |
Business Summary
Number of employees: 89
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Protein Kinase Inhibitors
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -40.39% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -40.39% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Laurent Guy
DFI | Director of Finance/CFO | - | 01-12-31 |
Chief Tech/Sci/R&D Officer | - | 18-03-31 | |
Alexis Bernard
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Patrick Moussy
BRD | Director/Board Member | - | 01-07-10 |
Director/Board Member | 62 | 21-06-26 | |
Director/Board Member | 66 | 21-06-26 | |
Director/Board Member | - | 21-06-26 | |
Renaud Sassi
BRD | Director/Board Member | - | 21-06-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 49,567,190 | 32,740,001 ( 66.05 %) | 0 | 66.05 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.54% | 106M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- AB Stock
- Company AB Science